Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104).

doi:10.1016/j.xcrm.2024.101615

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104).

Cell reports. Medicine - 16 Jul 2024

Zhang Chao, Sun Yu-Xuan, Yi Ding-Cheng, Jiang Ben-Yuan, Yan Li-Xu, Liu Ze-Dao, Peng Li-Shan, Zhang Wen-Jie, Sun Hao, Chen Zhi-Yong, Wang Dan-Hua, Peng Di, Chen Song-An, Li Si-Qi, Zhang Ze, Tan Xiao-Yue, Yang Jie, Zhao Zhang-Yi, Zhang Wan-Ting, Su Jian, Li Yang-Si, Liao Ri-Qiang, Dong Song, Xu Chong-Rui, Zhou Qing, Yang Xue-Ning, Wu Yi-Long, Zhang Ze-Min, Zhong Wen-Zhao

Abstract excerpt

The clinical efficacy of neoadjuvant immunotherapy plus chemotherapy remains elusive in localized epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Here, we report interim results of a Simon's two-stage design, phase 2 trial using neoadjuvant sintilimab with carboplatin and nab-paclitaxel in resectable EGFR-mutant NSCLC. All 18 patients undergo radical surgery, with one patient...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Albumins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal, Humanized

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Carboplatin

Share to Carcinoma, Non-Small-Cell Lung

Share to Circulating Tumor DNA

Share to Neoadjuvant Therapy

Share to Paclitaxel

Source

Open in PubMed Open full text

Identifiers

PMID: 38897205
DOI: 10.1016/j.xcrm.2024.101615
PMCID: PMC11293361

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104).PMID 38897205Read ↗

Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapySemantic proximity Read ↗

Immune and Circulating Tumor DNA Profiling After Radiation Treatment for Oligometastatic Non-Small Cell Lung Cancer: Translational Correlatives from a Mature Randomized Phase II Trial.Semantic proximity Read ↗

Autologous Cytokine-Induced Killer (CIK) Cell Immunotherapy plus Sintilimab and Chemotherapy in Advanced Non‒Small-Cell Lung Cancer: 3-Year Outcomes From the Phase Ib CCICC-002a StudySemantic proximity Read ↗

Neoadjuvant and Adjuvant Osimertinib in Stage IA to IIIA, EGFR-Mutant NSCLC (NORA).Semantic proximity Read ↗

The Design for a Phase II, Randomized, Multicenter Study of CtDNA-Guided Treatment With Furmonertinib Combined Therapy or Furmonertinib Alone for Untreated Advanced EGFR Mutant Non-small-cell Lung Cancer Patients: The FOCUS-C Study.Semantic proximity Read ↗

Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study.Semantic proximity Read ↗

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.Semantic proximity Read ↗

Sintilimab, Stereotactic Body Radiotherapy and Granulocyte-macrophage Colony Stimulating Factor as Second-line Therapy for Advanced Non-small Cell Lung Cancer: Safety Run-in Results of a Multicenter, Single-arm, Phase II TrialSemantic proximity Read ↗

Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study.Semantic proximity Read ↗

Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown.Semantic proximity Read ↗

The Adjuvant-Phase Dilemma After Neoadjuvant Chemoimmunotherapy in Resectable NSCLC: Evidence and Response-Guided StrategiesSemantic proximity Read ↗

Local consolidative therapy after EGFR-TKI response in advanced EGFR-mutant NSCLC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.